Pharmaceutical stocks hold a unique spot in the market, delivering steady demand and recurring revenue while offering exposure to fast-growing areas like oncology. Comparing AZN and BMY feels especially relevant right now, as both navigate the challenge of replacing aging blockbusters losing patent protection—but from very different starting points. This analysis speaks to income investors focused on dividend reliability, growth investors tracking pipeline catalysts, and traders monitoring relative momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
AstraZeneca focuses on oncology, biopharmaceuticals, and rare diseases. Recent quarterly results lifted sentiment after beating expectations, with revenue up roughly 7% on a constant-currency basis and core EPS rising about 19%, led by strong oncology contributions from Tagrisso, Imfinzi, Enhertu, and Calquence. These gains offset softness in older products like Farxiga and Brilinta now facing generics. The company reaffirmed full-year guidance and outlined a "Reshaping for Sustainable Growth" program aimed at roughly $1.5 billion in annual savings, much of which will go back into its pipeline of more than 180 projects. Management also plans to raise the 2026 dividend to $3.30 per share. These updates drove one of AZN's strongest single-day gains in a year, reversing earlier setbacks from clinical trial misses and shifting focus to an active catalyst calendar ahead.
Bristol Myers Squibb operates across oncology, hematology, immunology, and cardiovascular areas. Its latest quarter showed revenue growth of about 7%, helped by a 12% rise in the newer Growth Portfolio including Opdivo Qvantig, Breyanzi, Reblozyl, Camzyos, and Opdualag. Adjusted EPS, however, fell roughly 17% year over year amid higher acquired IPR&D charges and margin pressure. Management lifted full-year revenue guidance but cut earnings expectations due to those charges. The Legacy Portfolio, centered on Eliquis, faces a notable shift, with a projected $1.5 billion to $2 billion revenue step-down starting in 2027 as European exclusivity ends. Strong Eliquis demand has so far helped offset generic erosion elsewhere, and the stock has posted solid year-to-date gains on a roughly 4% dividend yield and attractive valuation for value investors.
The key difference lies in earnings direction. AZN is expanding both revenue and profits while holding guidance steady, supporting a more consistent upward trend. BMY, meanwhile, grows revenue but sees earnings pressure, with a guidance reduction and the large Eliquis patent expiry ahead. Valuation and income favor BMY, which trades at a lower P/E and higher yield, whereas AZN commands a premium multiple reflecting stronger growth prospects. Portfolio focus also diverges: AstraZeneca leans heavily into oncology and rare diseases with rapid growth potential but binary trial risks, while Bristol Myers offers more diversification yet remains tied to Eliquis for much of its legacy revenue. Recent price action shows AZN recovering more decisively after its earnings beat, while BMY has traded in a narrower range awaiting further catalysts.
Looking at trend consistency, earnings revision direction, guidance stability, and near-term catalyst depth, the AI currently leans toward AZN over BMY. AstraZeneca combines rising earnings, steady outlook, a dividend hike, and a rich pipeline calendar for a more stable, positively trending profile. Bristol Myers delivers clear value and income appeal, yet declining earnings and the approaching Eliquis cliff add near-term uncertainty. This view remains probabilistic and tied to present conditions, which can evolve with new data.
One resource I check regularly for a more systematic angle is Tickeron’s Trending AI Robots. The page highlights automated strategies performing well in current markets, spanning different styles, timeframes, and tickers. It helps narrow down approaches that align with specific objectives while reflecting shifting conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BMY moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 73%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BMY as a result. In 56 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 27 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 55%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +1.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 175 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
BMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 151 of 217 cases where BMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (-1.421). P/E Ratio (13.627) is within average values for comparable stocks, (21.700). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.038) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor